Setting

Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity

Published: 30 Dec 2021 | Report Code: 10248308 | Pages: 108

Asia Pacific monoclonal antibodies market will grow by 12.8% annually with a total addressable market cap of $414 billion over 2021-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies. Highlighted with 31 tables and 51 figures, this 108-page report “Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country. Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Human • Humanized • Chimeric • Murine Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Branded mAbs • Biosimilar mAbs Based on Production Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • In Vitro Production • In Vivo Production Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Cancer o Breast Cancer o Colorectal Cancer o Lung Cancer o Ovarian Cancer o Other Cancer Types • Autoimmune Diseases • Inflammatory Diseases • Infectious Diseases • Other Applications By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospitals • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories AbbVie, Inc. Amgen Inc. AstraZeneca plc Bayer AG Bristol-Myers Squibb Company Eli Lilly F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson & Johnson Merck & Co., Inc. Mylan N.V Norvatis AG Pfizer Sanofi S.A. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	22
2.2 Major Growth Drivers	24
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of Asia Pacific Market by Source	40
3.1 Market Overview by Source	40
3.2 Human	42
3.3 Humanized	43
3.4 Chimeric	44
3.5 Murine	45
4 Segmentation of Asia Pacific Market by Category	46
4.1 Market Overview by Category	46
4.2 Branded mAbs	48
4.3 Biosimilar mAbs	49
5 Segmentation of Asia Pacific Market by Production Type	50
5.1 Market Overview by Production Type	50
5.2 In Vitro Production	52
5.3 In Vivo Production	53
6 Segmentation of Asia Pacific Market by Application	54
6.1 Market Overview by Application	54
6.2 Cancer	56
6.2.1 Breast Cancer	58
6.2.2 Colorectal Cancer	59
6.2.3 Lung Cancer	60
6.2.4 Ovarian Cancer	61
6.2.5 Other Cancer Types	62
6.3 Autoimmune Diseases	63
6.4 Inflammatory Diseases	64
6.5 Infectious Diseases	65
6.6 Other Applications	66
7 Segmentation of Asia Pacific Market by End User	67
7.1 Market Overview by End User	67
7.2 Hospitals	69
7.3 Research Institutes	70
7.4 Other End Users	71
8 Asia-Pacific Market 2019-2030 by Country	72
8.1 Overview of Asia-Pacific Market	72
8.2 Japan	75
8.3 China	78
8.4 Australia	80
8.5 India	82
8.6 South Korea	84
8.7 Rest of APAC Region	86
9 Competitive Landscape	88
9.1 Overview of Key Vendors	88
9.2 New Product Launch, Partnership, Investment, and M&A	91
9.3 Company Profiles	92
Abbott Laboratories	92
AbbVie, Inc.	94
Amgen Inc.	95
AstraZeneca plc	96
Bayer AG	97
Bristol-Myers Squibb Company	98
Eli Lilly	99
F. Hoffmann-La Roche Ltd.	100
GlaxoSmithKline Plc	101
Johnson & Johnson	102
Merck & Co., Inc.	103
Mylan N.V	104
Norvatis AG	105
Pfizer	106
Sanofi S.A.	107
RELATED REPORTS	108
List Of Tables:


Table 1.  Snapshot of Asia Pacific Monoclonal Antibodies Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	21
Table 3. World Health Spending by Region, $ bn, 2013-2020	28
Table 4.  Main Product Trends and Market Opportunities in Asia Pacific Monoclonal Antibodies Market	32
Table 5. Asia Pacific Monoclonal Antibodies Market by Source, 2019-2030, $ bn	40
Table 6. Asia Pacific Monoclonal Antibodies Market by Category, 2019-2030, $ bn	46
Table 7. Asia Pacific Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn	50
Table 8. Asia Pacific Monoclonal Antibodies Market by Application, 2019-2030, $ bn	54
Table 9. Asia Pacific Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn	57
Table 10. Asia Pacific Monoclonal Antibodies Market by End User, 2019-2030, $ bn	67
Table 11. APAC Monoclonal Antibodies Market by Country, 2019-2030, $ bn	73
Table 12. Japan Monoclonal Antibodies Market by Source, 2019-2030, $ bn	77
Table 13. Japan Monoclonal Antibodies Market by Application, 2019-2030, $ bn	77
Table 14. Japan Monoclonal Antibodies Market by End User, 2019-2030, $ bn	77
Table 15. China Monoclonal Antibodies Market by Source, 2019-2030, $ bn	79
Table 16. China Monoclonal Antibodies Market by Application, 2019-2030, $ bn	79
Table 17. China Monoclonal Antibodies Market by End User, 2019-2030, $ bn	79
Table 18. Australia Monoclonal Antibodies Market by Source, 2019-2030, $ bn	81
Table 19. Australia Monoclonal Antibodies Market by Application, 2019-2030, $ bn	81
Table 20. Australia Monoclonal Antibodies Market by End User, 2019-2030, $ bn	81
Table 21. India Monoclonal Antibodies Market by Source, 2019-2030, $ bn	83
Table 22. India Monoclonal Antibodies Market by Application, 2019-2030, $ bn	83
Table 23. India Monoclonal Antibodies Market by End User, 2019-2030, $ bn	83
Table 24. South Korea Monoclonal Antibodies Market by Source, 2019-2030, $ bn	85
Table 25. South Korea Monoclonal Antibodies Market by Application, 2019-2030, $ bn	85
Table 26. South Korea Monoclonal Antibodies Market by End User, 2019-2030, $ bn	85
Table 27. Monoclonal Antibodies Market in Rest of APAC by Country/Region, 2019-2030, $ bn	87
Table 28. Abbott Laboratories: Company Snapshot	92
Table 29. Abbott Laboratories: Business Segmentation	92
Table 30. Abbott Laboratories: Product Portfolio	93
Table 31. Abbott Laboratories: Revenue, 2018-2020, $ bn	93
List of Figures:


Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. Asia Pacific Monoclonal Antibodies Market, 2019-2030, $ bn	19
Figure 5. Impact of COVID-19 on Business	22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Monoclonal Antibodies Market	24
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060	27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Monoclonal Antibodies Market	29
Figure 10. Investment Opportunity Analysis	33
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Monoclonal Antibodies Market	36
Figure 12. Breakdown of Asia Pacific Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue	41
Figure 13. Asia Pacific Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%)	41
Figure 14. Asia Pacific Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn	42
Figure 15. Asia Pacific Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn	43
Figure 16. Asia Pacific Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn	44
Figure 17. Asia Pacific Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn	45
Figure 18. Breakdown of Asia Pacific Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue	47
Figure 19. Asia Pacific Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%)	47
Figure 20. Asia Pacific Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn	48
Figure 21. Asia Pacific Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn	49
Figure 22. Breakdown of Asia Pacific Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue	51
Figure 23. Asia Pacific Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%)	51
Figure 24. Asia Pacific Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn	52
Figure 25. Asia Pacific Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn	53
Figure 26. Breakdown of Asia Pacific Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue	55
Figure 27. Asia Pacific Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%)	55
Figure 28. Asia Pacific Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn	56
Figure 29. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn	58
Figure 30. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn	59
Figure 31. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn	60
Figure 32. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn	61
Figure 33. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn	62
Figure 34. Asia Pacific Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn	63
Figure 35. Asia Pacific Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn	64
Figure 36. Asia Pacific Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn	65
Figure 37. Asia Pacific Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn	66
Figure 38. Breakdown of Asia Pacific Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue	68
Figure 39. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%)	68
Figure 40. Asia Pacific Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn	69
Figure 41. Asia Pacific Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn	70
Figure 42. Asia Pacific Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn	71
Figure 43. Breakdown of APAC Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue	73
Figure 44. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%)	74
Figure 45.  Monoclonal Antibodies Market in Japan, 2019-2030, $ bn	76
Figure 46.  Monoclonal Antibodies Market in China, 2019-2030, $ bn	78
Figure 47.  Monoclonal Antibodies Market in Australia, 2019-2030, $ bn	80
Figure 48.  Monoclonal Antibodies Market in India, 2019-2030, $ bn	82
Figure 49.  Monoclonal Antibodies Market in South Korea, 2019-2030, $ bn	84
Figure 50.  Monoclonal Antibodies Market in Rest of APAC, 2019-2030, $ bn	86
Figure 51. Growth Stage of Asia Pacific Monoclonal Antibodies Industry over the Forecast Period	88
Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)